mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.043 |
0.2 |
mRNA |
foretinib |
CTRPv2 |
pan-cancer |
AAC |
0.045 |
0.2 |
mRNA |
isoliquiritigenin |
CTRPv2 |
pan-cancer |
AAC |
-0.081 |
0.2 |
mRNA |
crizotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.044 |
0.2 |
mRNA |
PF-543 |
CTRPv2 |
pan-cancer |
AAC |
0.047 |
0.2 |
mRNA |
purmorphamine |
CTRPv2 |
pan-cancer |
AAC |
0.048 |
0.2 |
mRNA |
lapatinib |
gCSI |
pan-cancer |
AAC |
-0.067 |
0.2 |
mRNA |
BRD-K27188169:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.063 |
0.2 |
mRNA |
JQ-1:vorinostat (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.04 |
0.2 |
mRNA |
BCL-LZH-4 |
CTRPv2 |
pan-cancer |
AAC |
0.062 |
0.2 |